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Background and purpose. Breast-conserving surgery (BCS) and whole breast radiation (RT) with or without endocrine 33 
therapy (ET) represent the standard of care for ductal carcinoma in situ (DCIS). The use of adjuvant treatments after 34 
surgery is still controversial in this setting. We performed a retrospective multicenter analysis on a series of DCIS patients 35 
treated with BCS and adjuvant RT. 36 
Materials and methods. We collected clinical data from nine Italian centers on 1 072 women having a diagnosis of DCIS 37 
and treated between 1997 and 2012. We reported on the 5- and 10-year local recurrence (LR) rates, overall survival, and 38 
breast cancer specific survival (BCSS) employing the Kaplan-Meier method. 39 
Results. At a median follow-up of 8.4 years, 67 LR (6.3%) and 47 deaths (4.4%) were observed. LR rates at 5 and 10 40 
years were 3.4% and 7.6%, respectively. BCSS rates at 5 and 10 years were 99.7% and 99.1%, respectively. At univariate 41 
regression analysis, postmenopausal state (p=0.009), estrogen receptor (ER) (p=0.0001) and progesterone receptor 42 
(p=0.018) positivity and ET (p=0.006) were inversely correlated with LR. Final surgical margins (FSM) status <1 mm 43 
was significantly correlated with higher LR (p=0.003). At multivariate regression analysis postmenopausal state (p=0.03), 44 
and ER positive (p=0.045) maintained the significant favorable feature, while FSM <1 mm (p=0.024) confirmed its 45 
negative impact on LR. 46 
Conclusions. Our real-life study pointed out the significant favorable prognostic role of postmenopausal state and ER 47 
positive status on LR occurrence. FSM <1 mm was significantly correlated to a higher chance to experience LR. 48 
 49 
















Breast-conserving surgery (BCS) and postoperative whole breast radiotherapy (RT) with or without endocrine therapy 64 
(ET) still represent the standard treatment for most ductal carcinomas in situ (DCIS) [1-3]. 65 
Generally, RT can halve the risk of local recurrence, compared to BCS only, preventing both ipsilateral in situ and invasive 66 
relapse, without a clear benefit in terms of overall survival [4]. 67 
The ideal allocation of adjuvant treatments after surgery for DCIS is still controversial, since a consistent and reliable 68 
definition of risk categories is still lacking [5,6]. Therefore, tailoring treatment to specific patient’s needs, avoiding over- 69 
and under-treatment, is still an open issue [7]. 70 
While the benefit of ET on DCIS outcome is more controversial [3,8], recently published large studies confirmed the 71 
strong evidence in favor of routine postoperative RT after BCS, also considering that omitting radiation seems not to 72 
provide a higher breast preservation rate in case of local recurrence (LR) [9,10]. 73 
We performed a real-life multicenter national retrospective analysis on a large series of DCIS patients treated with BCS 74 
and adjuvant RT at tertiary referral hospitals in Italy, aiming at identifying reliable predictive and prognostic factors. 75 
 76 
Materials and methods 77 
Patients 78 
We collected data from nine Italian centers on 1 072 women having a diagnosis of DCIS, treated between 1997 and 2012 79 
with BCS and postoperative RT. Adjuvant ET administration, RT fractionation, and delivery of a boost dose to the tumor 80 
bed followed the policy of each Institution. 81 
One center enrolled more than 200 cases (University of Florence), five centers accrued between 100 and 200 patients 82 
(Brescia University and Spedali Civili, University Hospital of Modena, Humanitas Cancer Center and Research Hospital, 83 
National Cancer Institute of Milan, University of Perugia), and three centers included less than 100 cases (Azienda USL 84 
Toscana Centro, University of Turin, Sacro Cuore Don Calabria Hospital). 85 
Radiotherapy schedules (whole breast, tumor bed boost) are summarized in Table 1. Hypofractionation regimens were 86 
adopted as follow: 42.5 Gy in 16 fractions (University of Perugia, National Cancer Institute of Milan), 44 Gy in 16 87 
fractions (University of Florence, Brescia University and Spedali Civili).  88 
Clinical observation was mostly based on a 6-month clinical examination (years 1 to 5), that became yearly for years 5 to 89 
10 of follow up), together with annual bilateral mammography, A minority of patients lost to clinical follow up within 10 90 
years were contacted by phone, to update the vital status and disease control. 91 
 92 
Pathology methods 93 
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All the specimens were evaluated by expert pathologists dedicated to breast cancer. Estrogen receptor (ER) status and 94 
progesterone receptor (PgR) status were assessed; the expression scores were based on the percentages of positive nuclei 95 
over the total number of cancer cell nuclei counted. For ER and PgR status, two categories (negative and positive) were 96 
considered according to a widely used 10% cut-off values (both ER and PgR) [11]. Positive hormonal status (HS) was 97 
defined as positive ER and/or PgR status. Breast cancer was classified according to the histological type and staged 98 
following the TNM classification of malignant tumors [12]. Histological tumor grading was assessed according to Elston 99 
and Ellis [13]. Final surgical margins (FSM) status was stratified as follow: ≥10 mm, 1 to 9 mm, and <1 mm (0 to 0.9 100 
mm).  101 
 102 
Statistical analysis 103 
A descriptive analysis was performed to define the main individual characteristics of both patients and tumors. The 104 
survival analysis was carried out in relation to specific events, namely LR (total, DCIS, and invasive) or death (overall 105 
and breast cancer specific). We described the 5- and 10-year LR rates (both DCIS and invasive LR), overall survival 106 
(OS), and breast cancer specific survival (BCSS). The observation time was measured starting from the date of surgery 107 
to the date of LR observation, or date of death or the last follow-up for cases without events. 108 
Survival estimates were calculated according to the Kaplan-Meier method at the end of the follow-up. Differences 109 
between groups were evaluated by the log-rank test. Cox proportional regression analysis was used to determine the role 110 
of selected parameters on the risk of event occurrence by univariate models, and then by multivariate models including 111 
parameters statistically significant at univariate analysis. 112 
The risk of LR was calculated as hazard ratio (HR) with corresponding 95% confidence intervals (95% CI). P-values less 113 
than 0.05 were considered statistically significant. All statistical tests were performed using the IBM SPSS Statistics 114 
software (Statistical Package for Social Science, version 22). 115 
 116 
Results 117 
Patient characteristics 118 
Most of the patients were aged more than 40 years (97.6%) and postmenopausal (72.8%). The median age within the 119 
series was 57.2 years (mean 57.7 ±10.0 years). Tumors were mainly sized less than 10 mm (64.3%) and low-grade (G1-120 
2: 64.4%). Whole breast conventional fractionation (50 Gy in 25 fractions) was adopted in 886/1072 patients (82.6%), 121 
while hypofractionated RT schedules were used in 186/1072 patients (17.4%). Tumor bed RT boost was delivered in 122 
290/1072 cases (27.1%). Among them 36/290 patients (12.4%) had FSM <1 mm (61% of patients with FSM <1 mm). 123 
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ER status was available in 695 cases, and PgR status was available in 694 cases. Among the 557 patients affected by 124 
positive HS disease, 279 (50.1%) received adjuvant ET. No data about ET discontinuation and compliance over the 5-125 
year planned treatment was available. Main patient’s characteristics are summarized in Table 1. 126 
 127 
Outcomes 128 
At a median follow-up of 8.4 years (range 4-20 years), 67 LR (6.3%) and 47 deaths (4.4%) were observed. A DCIS LR 129 
was observed in 25/67 patients (37.3%) and an invasive LR in 42/67 patients (62.7%). The LR rates according to age 130 
(<40, 40-60, >60 years) by Kaplan Meier analysis were 20.5%, 32.2%, and 22.8%, respectively (log rank test p=0.40). 131 
We recorded four subsequent distant metastases, all of them after invasive LR. Overall 11/47 deaths (23.4%) were related 132 
to BC. We recorded 36 contralateral breast cancers (3.4%). DCIS HS was known for 19 of them and was positive in 13/19 133 
cases (4/13 received previous adjuvant ET). 134 
Mean time to LR was 7 (SD±5) years (5.4 years and 8 years for DCIS and invasive LR, respectively). The LR rates at 5 135 
and 10 years were 3.4% (95% CI 2.3-4.5) and 7.6% (95% CI 6.0-9.2), respectively. LR rate curves (all, DCIS, and 136 
invasive) are shown in Figure 1A-C. 137 
The OS rates at 5 and 10 years were 98.5% and 97%, respectively; the BCSS rates at 5 and 10 years were 99.7% and 138 
99.1%, respectively. 139 
At univariate regression analysis, postmenopausal status (HR 0.52; 95% CI 0.32-0.85, p=0.009), ER positive status (HR 140 
0.32; 95% CI 0.17-0.60, p=0.0001), PgR positive status (HR 0.46; 95% CI 0.25-0.88, p=0.018), and adjuvant ET (HR 141 
0.39; 95% CI 0.20-0.77, p=0.006) were inversely correlated to LR risk. Conversely, FSM <1 mm on the definitive 142 
pathological specimen was directly correlated with LR risk (HR 3.25; 95% CI 1.49-7.08, p=0.003). Both hypofractionated 143 
RT (p=0.10) and tumor bed RT boost delivery (p=0.34) showed no significant impact on LR rate. 144 
At multivariate regression analysis post-menopausal status (HR 0.40; 95% CI 0.18-0.92, p=0.03; Figure 2), and positive 145 
ER status (HR 0.35; 95% CI 0.13-0.98, p=0.045; Figure 3) confirmed their significant favorable effect on LR risk, while 146 
FSM <1 mm (HR 3.3; 95% CI 1.17-9.28, p=0.024; Figure 4) confirmed its negative impact on LR.  Univariate and 147 
multivariate analyses results are summarized in Table 2. 148 
Focusing on the impact of adjuvant ET among the HS positive group of patients (279 out of 557), no significant effect 149 
was observed in terms of all LR (p=0.34), DCIS LR (p=0.92), invasive LR (p=0.25), and OS (p=0.81). 150 





Our experience represents one of the largest published national multicenter analyses on DCIS patients treated with BCS 154 
followed by postoperative radiation, with or without ET. Adjuvant RT after BCS led to a low rate of LR over time, below 155 
8% at 10 years. This is a lower rate than that observed in the population-based Munich Cancer Registry, which described 156 
a cumulative incidence of ipsilateral in-breast tumor recurrence of 13.6% at 10 years [14], but similar to what reported in 157 
the SEER database (11%) [15], NSABP-B17 trial (8%) [1], or in the EORTC 10853 trial (8%) [16]. 158 
Interestingly, we observed a relatively high rate of invasive LR (over 60%), compared to the commonly reported rate of 159 
50% [16,17]. We do not have any specific explanation for this finding, apart from observing that few series reported rates 160 
of invasive LR close to 60%, such as the MD Anderson Cancer Center series used to externally validate the Memorial 161 
Sloan Kettering Cancer Center nomogram for DCIS (57% rate of invasive recurrence) [18]. Other series reported an even 162 
higher invasive LR rate such as in Vidali et al (63%) [19], which is a retrospective analysis on a population treated in 163 
Italy, and in Shaitelman et al (76%) [20]. Main recently published studies on DCIS receiving postoperative whole breast 164 
radiotherapy [14,19,21-23] were reported in Table 3. 165 
The assessment of FSM width could be affected by several biases: whole organ sectioning, radiological-pathological 166 
correlations of mastectomy specimens, technical limitations including excessive compression for specimen radiography, 167 
surface ink tracking deeper into specimen portions, tumor-to-ink distance on any slide not being representative of the 168 
entire specimen [24]. Therefore, the ideal FSM threshold is still strongly debated. 169 
In our series the FSM status resulted as the most relevant predictive factor for LR, similarly to several published studies. 170 
The risk for LR was shown to be more than 3-time higher for patients with FSM <1 mm (HR 3.3; 95%CI 1.17-9.28, 171 
p=0.024). In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial [25], the annual rate for 172 
ipsilateral breast LR after surgery alone was 8.1% in patients with positive FSM compared to 3.3% in patients without, 173 
and it was reduced after whole breast RT to 2.7% and 1.2%, respectively. 174 
Van Zee et al [26], found no difference in LR risk between ≤2 mm margins and wider resection in patients receiving 175 
whole breast RT. Conversely, a meta-analysis published in 2016 compared specific FSM width thresholds (2, 3, 5, and 176 
10 mm) with negative margins (defined as >0 mm or 1 mm). The odds of LR and the 10-year probability of recurrences 177 
were much lower in case of the wider margins [27]. Indeed, the Society of Surgical Oncology-American Society for 178 
Radiation Oncology-American Society of Clinical Oncology Consensus guidelines on FSM for BCS treated with whole-179 
breast RT in DCIS, recommend the use of a 2-mm margin as the standard for an adequate FSM, since it is associated with 180 
lower rates of LR and has the potential to decrease re-excision rates, to improve cosmetic outcomes, and to decrease 181 
health care costs [28]. 182 
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However, clinical judgment should always determine which patients having negative margin would require re-excision. 183 
In carefully selected patients with close (< 2 mm) or focally/minimally involved margins, re-excision was avoided with 184 
satisfactory local control achieved by increasing the radiation dose to the tumor bed to at least 66 Gy [29]. 185 
The risk assessment for LR should include the following: residual calcifications on post-excision mammography, extent 186 
of DCIS close to the margin, cosmetic impact assessment, comorbidity, and overall patient expectation [1,30]. 187 
In our experience inadequate FSM confirmed its strong negative impact on LR rate, independently of the use of a RT 188 
boost to the tumor bed. However, no definitive conclusions on the RT boost role could be drawn from this study, since 189 
its use was heterogeneous and not strictly related to the FSM status. Indeed, it is well-known that tumor bed RT boost is 190 
able to reduce but not fully overcome the negative impact of an inadequate FSM status on LR rate [23,31-36]. 191 
Randomized data are upcoming, including the multicentric BONBIS French study to evaluate the impact of a localized 192 
16 Gy boost after BCS [37], and the Australian-led Breast International Group (BIG) 03-07/Trans-Tasman Radiation 193 
Oncology Group (TROG) 07.01 phase III trial evaluating lumpectomy boost after whole-breast RT. The results of TROG 194 
trial will clarify also the role of hypofractionated RT in DCIS patients, a still debated issue. However, a meta-analysis of 195 
observational studies published in 2015 [38], showed the hypofractionation as a safe option for DCIS patients, and our 196 
analysis seems to confirm this data, despite our small sample size. 197 
In a multicenter collaborative effort at three Canadian institutions (440 patients), excellent local control for DCIS 198 
undergoing BCS treated with hypofractionated RT using 42.5 Gy in 16 fractions was shown [39]. 199 
Moreover, Offersen and colleagues have recently the updated results of the DBCG HYPO trial [40], confirming the 200 
efficacy and safety of hypofractionation for DCIS treatment, with a low LR risk. 201 
Adjuvant ET after BCS demonstrated a significant benefit only in selected patients and is not currently accepted as a 202 
standard of care for HS positive DCIS, due to the potential overtreatment and toxicity profile [3,8]. The UK/ANZ DCIS 203 
trial did not find a benefit in the use of tamoxifen in RT group [3], and in the NSABP B-24 protocol [8] tamoxifen was 204 
beneficial only in the subgroup of patients with positive margins (24%). 205 
Almost half of our treated patients had positive HS, and around half of them received adjuvant ET. Although our results 206 
showed an independent protective role for postmenopausal status and positive ER status, the use of adjuvant ET seemed 207 
not to impact on patient survival outcomes. Thus, a positive HS disease seems to be an intrinsic biological protective 208 
factor. Indeed, it has been reported by several published experiences the possible negative impact on outcome of a negative 209 
HS [41-44], while older age and postmenopausal status seemed to be associated with better prognosis [45]. 210 
However, we have to take into account study limitations while interpreting our results, mainly related to the retrospective 211 
nature of the analysis. A median follow-up close to 8 years is probably too short to allow any definitive conclusions on 212 
impact of treatment on OS and BCSS. Moreover, we should consider the different practice among centers on the 213 
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application of hypofractionated schedule or boost to the tumor bed, the missing information about compliance/adherence 214 
for ET, and the so-called ‘healthy user effect’ which is a well-established source of sampling bias in observational studies 215 
dealing with early-stage breast cancer patients [46]. 216 
In conclusions, our study pointed out the significant favorable predictive role of the postmenopausal and positive ER 217 
status with respect to LR occurrence. FSM <1 mm was the most relevant independent risk factor for LR. Prospective data 218 
are needed to investigate the benefit of adjuvant therapy for DCIS and to better define a reliable risk-groups stratification. 219 
Undoubtedly, a strong cooperation with breast surgeons in a multidisciplinary setting is highly recommended. 220 
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Figure captions 354 
Figure 1. LRFS Kaplan-Meier curves: all LR (Figure 1A), DCIS LR (Figure 1B), and invasive LR recurrence rates 355 
(Figure 1C). 356 
Figure 2. LR recurrence rate curves comparing premenopausal (dotted line) to postmenopausal status (solid line; HR 357 
0.40; 95% CI 0.18-0.92, p=0.03). 358 
Figure 3. LR recurrence rate curves comparing estrogen receptor (ER) negative (dotted line) to ER positive status (solid 359 
line; HR 0.35; 95% CI 0.13-0.98, p=0.045). 360 
Figure 4. LR recurrence rate curves stratified by final surgical margins (FSM) status: ≥10 mm (dashed line), 1 to 9 mm 361 
(dotted line), and <1 mm (solid line; HR 3.3; 95%CI 1.17-9.28, p=0.024). 362 
